FDA Approves Lotilaner Ophthalmic Solution for Treatment of

Granted to Tarsus Pharmaceuticals, the approval of lotilaner ophthalmic solution 0.25% marks the first-and-only FDA-approved therapeutic for Demodex blepharitis, a common eyelid disease.

Related Keywords

Selina Mcgee , Bobak Azamian , Christopher Starr , Drug Administration , Tarsus Pharmaceuticals Inc , Tarsus Pharmaceuticals , Weill Cornell Medicine , New York Presbyterian Hospital ,